Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)
Yevgeniy Balagula, Katherine Barth Huston, Klaus J. Busam, Mario E. Lacouture, Paul B. Chapman, Patricia L. MyskowskiVolume:
29
Language:
english
Pages:
8
DOI:
10.1007/s10637-010-9567-3
Date:
October, 2011
File:
PDF, 457 KB
english, 2011